興森科技(002436.SZ):興森股權擬以7000萬元出售華榮科技20%股權
格隆匯5月12日丨興森科技(002436.SZ)公佈,公司下屬控股子公司興森股權投資(廣州)合夥企業(有限合夥)(“興森股權”)持有深圳市華榮科技有限公司(“標的公司”或“華榮科技”)20%股權。興森股權以人民幣7000萬元將標的公司20%股權轉讓給和平電子(深圳)有限公司(“和平電子”),並已於2021年2月25日簽訂了《股權轉讓協議書》。
標的公司成立於2001年8月,是一家EMS廠商,業務覆蓋天饋、企業網、能基、傳輸、網絡、無線總裝業務。
此次交易產生的投資收益約-1580萬元(未經審計),具體數據將以公司經審計的財務報吿數據為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.